Gating function of isoleucine-116 in TM-3 (position III:16/3.40) for the activity state of the CC-chemokine receptor 5 (CCR5)

British Journal of Pharmacology

Volumn 171, Issue 6, 2014, Pages 1566-1579

  Steen, A ^b   Sparre Ulrich, A H ^b   Thiele, S ^b   Guo, D ^b   Frimurer, T M ^c   Rosenkilde, M M ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Capital Region   (Denmark)

Author keywords

7TM; arrestin; biased signalling; CCR5; chemokines; computer modelling; constitutive activity; GPCR; superagonist; US28

Indexed keywords

BETA ARRESTIN; CHEMOKINE RECEPTOR CCR5; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOLEUCINE; MEMBRANE PROTEIN; PHENYLALANINE; TM 3 PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING COMPETITION; CELL MEMBRANE; CHANNEL GATING; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; MOLECULAR DOCKING; MOLECULAR PHYLOGENY; MUTATION RATE; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

7TM; ARRESTIN; BIASED SIGNALLING; CCR5; CHEMOKINES; COMPUTER MODELLING; CONSTITUTIVE ACTIVITY; GPCR; SUPERAGONIST; US28;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; ION CHANNEL GATING; ISOLEUCINE; MOLECULAR SEQUENCE DATA; RECEPTORS, CCR5; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84895736645     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12553     Document Type: Article

References (62)

1. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, et al. (2008). Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 122: 769-776.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The concise guide to pharmacology 2013/2014. G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. (1999). A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 96: 5698-5703. (Pubitemid 29234681)
4. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, et al. (1998). G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391: 86-89. (Pubitemid 28079220)
5. Baldwin JM, (1993). The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12: 1693-1703. (Pubitemid 23112824)
6. Ballesteros JA, Weinstein H, (1995). Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25: 366-428.
7. Barth P, Schonbrun J, Baker D, (2007). Toward high-resolution prediction and design of transmembrane helical protein structures. Proc Natl Acad Sci U S A 104: 15682-15687. (Pubitemid 350035360)
8. Beisser PS, Verzijl D, Gruijthuijsen YK, Beuken E, Smit MJ, Leurs R, et al. (2005). The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J Virol 79: 441-449. (Pubitemid 39648397)
9. Bodaghi B, Jones TR, Zipeto D, Vita C, Sun L, Laurent L, et al. (1998). Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus- infected cells. J Exp Med 188: 855-866. (Pubitemid 28433412)
10. Bottegoni G, Kufareva I, Totrov M, Abagyan R, (2009). Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. J Med Chem 52: 397-406.
11. Casarosa P, Bakker RA, Verzijl D, Navis M, Timmerman H, Leurs R, et al. (2001). Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J Biol Chem 276: 1133-1137. (Pubitemid 32096538)
12. Cho W, Taylor LP, Akil H, (1996). Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction. Mol Pharmacol 50: 1338-1345. (Pubitemid 26384873)
13. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666. (Pubitemid 26197679)
14. Feng Y, Broder CC, Kennedy PE, Berger EA, (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877. (Pubitemid 26154590)
15. Greasley PJ, Fanelli F, Scheer A, Abuin L, Nenniger-Tosato M, DeBenedetti PG, et al. (2001). Mutational and computational analysis of the alpha(1b)-adrenergic receptor. Involvement of basic and hydrophobic residues in receptor activation and G protein coupling. J Biol Chem 276: 46485-46494.
16. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O, (2010). New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307-321.
17. Holst B, Nygaard R, Valentin-Hansen L, Bach A, Engelstoft MS, Petersen PS, et al. (2010). A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J Biol Chem 285: 3973-3985.
18. Katoh K, Misawa K, Kuma K-I, Miyata T, (2002). MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 30: 3059-3066. (Pubitemid 34851225)
19. Kissow H, Hartmann B, Holst JJ, Viby N-E, Hansen LS, Rosenkilde MM, et al. (2012). Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 179: 91-100.
20. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, et al. (1997). A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277: 1656-1659. (Pubitemid 27446226)
21. Kledal TN, Rosenkilde MM, Schwartz TW, (1998). Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. FEBS Lett 441: 209-214. (Pubitemid 29027897)
22. Kostenis E, Zeng FY, Wess J, (1998). Functional characterization of a series of mutant G protein alphaq subunits displaying promiscuous receptor coupling properties. J Biol Chem 273: 17886-17892. (Pubitemid 28355136)
23. Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, et al. (2011). ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 487: 545-574.
24. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AGW, et al. (2011). Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474: 521-525.
25. Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K, (2012). Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science 335: 1106-1110.
26. Lüttichau HR, Johnsen AH, Jurlander J, Rosenkilde MM, Schwartz TW, (2007). Kaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3. J Biol Chem 282: 17794-17805. (Pubitemid 47100328)
27. Lyngaa R, Nørregaard K, Kristensen M, Kubale V, Rosenkilde MM, Kledal TN, (2010). Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. Oncogene 29: 4388-4398.
28. McLean KA, Holst PJ, Martini L, Schwartz TW, Rosenkilde MM, (2004). Similar activation of signal transduction pathways by the herpesvirus-encoded chemokine receptors US28 and ORF74. Virology 325: 241-251. (Pubitemid 38902790)
29. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, et al. (2004). Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78: 8654-8662. (Pubitemid 39025131)
30. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, et al. (2006). Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281: 12688-12698. (Pubitemid 43855359)
31. Marie J, Koch C, Pruneau D, Paquet JL, Groblewski T, Larguier R, et al. (1999). Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI. Mol Pharmacol 55: 92-101. (Pubitemid 29042526)
32. Maussang D, Verzijl D, van Walsum M, Leurs R, Holl J, Pleskoff O, et al. (2006). Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci U S A 103: 13068-13073. (Pubitemid 44338917)
33. Mirzadegan T, Benkö G, Filipek S, Palczewski K, (2003). Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42: 2759-2767. (Pubitemid 36331518)
34. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, et al. (1993). Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365: 649-651. (Pubitemid 23350535)
35. Parnot C, Bardin S, Miserey-Lenkei S, Guedin D, Corvol P, Clauser E, (2000). Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay. Proc Natl Acad Sci U S A 97: 7615-7620. (Pubitemid 30431512)
36. Paulsen SJ, Rosenkilde MM, Eugen-Olsen J, Kledal TN, (2005). Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J Virol 79: 536-546. (Pubitemid 39648406)
37. Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, et al. (2012). Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A 109: 6733-6738.
38. Rasmussen SG, Jensen AD, Liapakis G, Ghanouni P, Javitch JA, Gether U, (1999). Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Mol Pharmacol 56: 175-184. (Pubitemid 29309827)
39. Rasmussen SGF, Choi H-J, Fung JJ, Pardon E, Casarosa P, Chae PS, et al. (2011a). Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 469: 175-180.
40. Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. (2011b). Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
41. Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, et al. (2007). Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem 282: 18028-18036. (Pubitemid 47100250)
42. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD, (1992). Constitutively active mutants of rhodopsin. Neuron 9: 719-725.
43. Rosenkilde MM, (2005). Virus-encoded chemokine receptors-putative novel antiviral drug targets. Neuropharmacology 48: 1-13. (Pubitemid 40022910)
44. Rosenkilde MM, Schwartz TW, (2000). Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. Mol Pharmacol 57: 603-609.
45. Rosenkilde MM, McLean KA, Holst PJ, Schwartz TW, (2004). The CXC chemokine receptor encoded by herpesvirus saimiri, ECRF3, shows ligand-regulated signaling through Gi, Gq, and G12/13 proteins but constitutive signaling only through Gi and G12/13 proteins. J Biol Chem 279: 32524-32533. (Pubitemid 39014708)
46. Rosenkilde MM, Kledal TN, Schwartz TW, (2005). High constitutive activity of a virus-encoded seven transmembrane receptor in the absence of the conserved DRY motif (Asp-Arg-Tyr) in transmembrane helix 3. Mol Pharmacol 68: 11-19. (Pubitemid 41002940)
47. Schwartz TW, (1994). Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5: 434-444. (Pubitemid 24254296)
48. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE, (2006). Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu Rev Pharmacol Toxicol 46: 481-519. (Pubitemid 43271198)
49. Semple G, Skinner PJ, Gharbaoui T, Shin Y-J, Jung J-K, Cherrier MC, et al. (2008). 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem 51: 5101-5108.
50. Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki N, et al. (2000). Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 43: 2049-2063. (Pubitemid 30340944)
51. Spalding TA, Burstein ES, Henderson SC, Ducote KR, Brann MR, (1998). Identification of a ligand-dependent switch within a muscarinic receptor. J Biol Chem 273: 21563-21568. (Pubitemid 28405325)
52. Standfuss J, Edwards PC, D'Antona A, Fransen M, Xie G, Oprian DD, et al. (2011). The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471: 656-660.
53. Steen A, Thiele S, Guo D, Hansen LS, Frimurer TM, Rosenkilde MM, (2013). Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7. J Biol Chem 288: 12511-12521.
54. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, et al. (2013). Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341: 1387-1390.
55. Thiele S, Steen A, Jensen PC, Mokrosinski J, Frimurer TM, Rosenkilde MM, (2011). Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J Biol Chem 286: 37543-37554.
56. Totrov M, Abagyan R, (2008). Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol 18: 178-184.
57. Valentin-Hansen L, Holst B, Frimurer TM, Schwartz TW, (2012). PheVI:09 (Phe6.44) as a sliding micro-switch in 7TM G protein-coupled receptor activation. J Biol Chem 287: 43516-43526.
58. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM, (2013). Molecular signatures of G-protein-coupled receptors. Nature 494: 185-194.
59. Viola A, Luster AD, (2008). Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48: 171-197. (Pubitemid 351756361)
60. Warne T, Edwards PC, Leslie AGW, Tate CG, (2012). Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 20: 841-849.
61. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al. (2011). Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235-242.
62. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, et al. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.